HSDT (Helius Medical Technologies) Cash-to-Debt : 150.78 (As of Sep. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Helius Medical Technologies Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Helius Medical Technologies's cash to debt ratio for the quarter that ended in Sep. 2024 was 150.78.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Helius Medical Technologies could pay off its debt using the cash in hand for the quarter that ended in Sep. 2024.

The historical rank and industry rank for Helius Medical Technologies's Cash-to-Debt or its related term are showing as below:

HSDT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.96 Med: 141.72 Max: No Debt
Current: 150.78

During the past 10 years, Helius Medical Technologies's highest Cash to Debt Ratio was No Debt. The lowest was 0.96. And the median was 141.72.

HSDT's Cash-to-Debt is ranked better than
88.76% of 863 companies
in the Medical Devices & Instruments industry
Industry Median: 1.85 vs HSDT: 150.78

Helius Medical Technologies Cash-to-Debt Historical Data

The historical data trend for Helius Medical Technologies's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Helius Medical Technologies Cash-to-Debt Chart

Helius Medical Technologies Annual Data

Trend

Mar14

Mar15

Mar16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

8.57

36.60

3,668.33

132.26

90.91

Helius Medical Technologies Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Cash-to-Debt	Get a 7-Day Free Trial															94.23	90.91	79.09	182.49	150.78

Competitive Comparison of Helius Medical Technologies's Cash-to-Debt

For the Medical Devices subindustry, Helius Medical Technologies's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Helius Medical Technologies's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Helius Medical Technologies's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Helius Medical Technologies's Cash-to-Debt falls into.

Helius Medical Technologies Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Helius Medical Technologies's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	5.182	/	(0.045	+	0.012)
	=	90.91

Helius Medical Technologies's Cash to Debt Ratio for the quarter that ended in Sep. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	3.468	/	(0.023	+	0)
	=	150.78

Helius Medical Technologies (NAS:HSDT) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Helius Medical Technologies Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Helius Medical Technologies's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Helius Medical Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Helius Medical Technologies Inc (NAS:HSDT) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

642 Newtown Yardley Road, Suite 100, Newtown, PA, USA, 18940

Website

https://www.heliusmedical.com

Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS), is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.

Executives

Dane Andreeff	director, 10 percent owner, officer: President and CEO	C/O ANDREEFF EQUITY ADVISORS L.L.C., 140 E. ST. LUCIA LANE, SANTA ROSA BEACH FL 32459
Jeffrey S Mathiesen	director, officer: CFO and Treasurer	43334 SEVEN MILE RD., SUITE 1000, NORTHVILLE MI 48167
Favit-van Pelt Antonella R.	officer: Chief Medical Officer	C/O HELIUS MEDICAL TECHNOLOGIES, INC., 642 NEWTOWN YARDLEY ROAD, NEWTOWN PA 18940
Paul Buckman	director	12988 VALLEY VIEW RD, EDEN PRAIRIE MN 55402
Sherrie L Perkins	director	5033 TANGLE LANE, HOUSTON TX 77056
Jennifer Laux	officer: Chief Commercial Officer	642 NEWTOWN YARDLEY ROAD, SUITE 100, NEWTOWN PA 18940
Thomas E Griffin	director	C/O ENTELLUS MEDICAL, INC., 3600 HOLLY LANE NORTH, SUITE 40, PLYMOUTH MN 55447
Blane Walter	director	500 OLDE WORTHINGTON ROAD, WESTERVILLE OH 43082
Edward M Straw	director	C/O ESTEE LAUDER COMPANIES, 767 FIFTH AVENUE, NEW YORK NY 10153
Joyce N Laviscount	officer: See Remarks	100 ENDO BOULEVARD, CHADDS FORD PA 19317
Huaizheng Peng	director	HELIUS MEDICAL TECHNOLOGIES, INC., SUITE 400, 41 UNIVERSITY DRIVE, NEWTOWN PA 18940
Philippe Deschamps	director, 10 percent owner, officer: President & CEO	105 BRADFORD RD, SUITE 420, WEXFORD PA 15090
Mitch E Tyler	director	HELIUS MEDICAL TECHNOLOGIES, INC., SUITE 400, 41 UNIVERSITY DRIVE, NEWTOWN PA 18940
Jonathan Sackier	10 percent owner, officer: Chief Medical Officer	HELIUS MEDICAL TECHNOLOGIES, INC., SUITE 400, 41 UNIVERSITY DRIVE, NEWTOWN PA 18940
A&b (hk) Co Ltd	10 percent owner	8/F BLDG A TONGFANG INFORMATION HARBOR, NO 11 LANGSHAN ROAD NANSHAN DISTRICT, SHENZHEN F4 518057